Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The purpose of this study is to investigate the efficacy of umbilical cord mesenchymal stem cells (MSCs) infusion via hepatic artery in the treatment of liver cirrhosis.
To investigate the efficacy of umbilical cord mesenchymal stem cells (MSCs) infusion via hepatic artery in the treatment of liver cirrhosis. Patients with liver cirrhosis were randomly separated into two groups. Umbilical cord MSCs were infused to patients using interventional method via hepatic artery for One group. After the catheter placed at proper hepatic artery was confirmed by angiography, umbilical cord MSCs were infused slowly for 15-20minutes. The control group accepted conserved therapy.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| umbilical cord mesenchymal stem cells | Experimental | Umbilical cord mesenchymal stem cells were infused to patients using interventional method via hepatic artery. After the catheter placed at proper hepatic artery was confirmed by angiography,umbilical cord MSCs were infused slowly for 15-20minutes. |
|
| Conserved therapy | Active Comparator | Patients received comprehensive treatment including antiviral drugs, lowering aminotransferase and jaundice medicine. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| umbilical cord Mesenchymal Stem Cells | Biological | Umbilical cord mesenchymal stem cells were infused to patients using interventional method via hepatic artery. After the catheter placed at proper hepatic artery was confirmed by angiography,umbilical cord MSCs were infused slowly for 15-20minutes. |
| Measure | Description | Time Frame |
|---|---|---|
| The result of liver function and liver histological improvement. | every 4 weeks |
| Measure | Description | Time Frame |
|---|---|---|
| The disappearance or reduction of abdominal dropsy | every 4 weeks | |
| The clinical symptom improve(including food appetite,debilitation,abdominal distension,edema of lower limbs ) | every 4 weeks |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Jianxia Hu, MD | Contact | 86-0532-82911676 | qdyxyhjx@126.com | |
| Hong Gao, MS | Contact | 86-0532-82911676 | honggaogloria@gmail.com |
| Name | Affiliation | Role |
|---|---|---|
| Zibin Tian, MD | The Affiliated Hospital of Qingdao University | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Stem Cell Research Center of Medical School Hospital of Qingdao University | Qingdao | Shandong | 266003 | China |
Not provided
| ID | Term |
|---|---|
| D008103 | Liver Cirrhosis |
| ID | Term |
|---|---|
| D008107 | Liver Diseases |
| D004066 | Digestive System Diseases |
| D005355 | Fibrosis |
| D010335 | Pathologic Processes |
Not provided
Not provided
| ID | Term |
|---|---|
| D004358 | Drug Therapy |
| ID | Term |
|---|---|
| D013812 | Therapeutics |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
|
|
| Conserved therapy | Drug | Oral or intravenous administration |
|
|
| D013568 |
| Pathological Conditions, Signs and Symptoms |